Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Apremilast: Oral apremilast 30 mg BD, starting at 10 mg/day with an increment of 10 mg/day over 5 days, for 8 weeks.
Intervention2: Methotrexate plus apremilast: Oral methotrexate 0.2 m
Sponsors
Department of Dermatology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of psoriasis vulgaris requiring systemic therapy. (Body surface area > 10% or PASI score > 10 or non-responsive to topical therapy) 2. Patients above the age of 18 years. 3. Patients consenting for contraception required for methotrexate therapy.
Exclusion criteria
Exclusion criteria: 1. Patients suffering from any other significant systemic illness. 2. History of anti-psoriatic treatment in the last 2 months. 3. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of apremilast and methotrexate and their combination in patients of psoriasis vulgaris by comparing the PASI score before and after commencement of the therapy. Timepoint: 0,2,4,6,8 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety of all the three treatment modalities by assessing the side effects.Timepoint: 0,2,4,6,8 weeks. | — |
Countries
India
Contacts
Public ContactDr Nainika Goel
Government Medical College and Hospital, Chandigarh
Outcome results
None listed